GleamWall
中文EN

TCRT Alaunos Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1107421 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY10.0%
TTM EPS YoY39.1%
Revenue 3-yr CAGR-41.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-121,033.3%
Net margin-120,766.7%
FCF margin—
EBITDA margin-119,966.7%

Returns

ROE-192.0%
ROA-128.4%
ROIC (approx.)-469.9%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio1.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-46.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$5,000$10,000
R&D expense$1.36M$362,000
SG&A expense$2.87M$4.46M
Operating income-$4.22M-$4.81M
Interest expense—$0
Income tax$0—
Net income-$4.18M-$4.68M
EBITDA-$4.22M-$4.81M
EPS (basic)-2.20-2.92
EPS (diluted)-2.20-2.92
Weighted avg. shares (diluted)1.95M1.60M
Balance sheet
Cash & equivalents$1.39M$1.09M
Receivables$3,000$5,000
Current assets$1.99M$2.75M
PP&E, net$91,000$0
Total assets$2.97M$2.75M
Current liabilities$813,000$692,000
Long-term debt—$0
Total debt—$0
Total liabilities$813,000$692,000
Shareholders' equity$2.15M$2.06M
Net debt—-$1.09M
Shares outstanding2.35M1.60M
Cash flow statement
Operating cash flow-$2.87M-$4.97M
Capital expenditure$98,000$0
Free cash flow-$2.97M-$4.97M
Investing cash flow-$98,000$0
Financing cash flow$3.26M$0
Depreciation & amortization$7,000$2,000
Stock-based compensation$796,000$435,000

Free plan shows the latest 2 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.